Biote corp.

biote Corp. Up to 72,069,990 Shares of Class A Common Stock . Up to 67,856,462 Shares of Class A Common Stock . Up to 5,566,666 Warrants . This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-265714), as amended.Dec 13, 2021 · Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III Biote is a high-growth medical practice-building company operating within the multi-billion dollar ... Dec 1, 2023 · As of December 01, 2023, biote Corp had a $363.1 million market capitalization, putting it in the 52nd percentile of companies in the Professional Information Services industry. biote Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. biote Corp’s trailing 12-month revenue is $184.1 million with a ... American International Group Inc. acquired a new position in biote Corp. (NASDAQ:BTMD – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 6,739 shares of the company’s stock, valued at approximately $46,000. Other institutional investors and …

2023 Third Quarter Financial Review. Revenue for the third quarter of 2023 was $45.6 million, an increase of 8.5% from $42.0 million for the third quarter of 2022. The increase in revenue was driven by procedure revenue growth of 7.4% and dietary supplement revenue growth of 5.1%. As expected, third quarter dietary supplement revenue growth ...As previously disclosed, on May 9, 2023, biote Corp. (the “Company”), commenced (i) its offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share (“Common Stock”), of the Company, at an exercise price of $11.50 per share (the …

Dec 1, 2023 · As of December 01, 2023, biote Corp had a $363.1 million market capitalization, putting it in the 52nd percentile of companies in the Professional Information Services industry. biote Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. biote Corp’s trailing 12-month revenue is $184.1 million with a ... Biote Appoints Samar Kamdar as Chief Financial Officer IRVING, TX, August 24, 2022 — biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer.

Get the latest biote Corp (BTMD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. IRVING, Texas--(BUSINESS WIRE)--Jun. 22, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, has announced the launch of a new Men’s Health Division with the mission of redefining wellness for men through innovation in hormone education and optimization.biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical ... Revenue for the first quarter of 2023 was $44.8 million, an increase of 20.7% from $37.1 million for the first quarter of 2022. The increase was driven by procedure revenue growth of 13.8% and dietary supplement revenue growth of 46.0%. Gross profit margin for the first quarter of 2023 was 69.1% compared to 66.9% for the first quarter of 2022.IRVING, Texas -- (BUSINESS WIRE)--Nov. 7, 2023-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third quarter ended September 30, 2023 .

May 31, 2022 · Biote Corp. biote Corp. provides precision and preventive medicines. The Company offers hormone therapy and products that boosts energy and immune system. biote serves customers worldwide.

Biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels.

About Biote. Founded in 2012, Biote has experience phenomenal growth over the last decade. The Biote state-of-the-art training facility hosts physicians, healthcare providers, and medical staff members monthly during the Biote Method learning and certification process. To date, more than 6,400 medical practitioners have successfully completed ...Oct 24, 2023 · Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call. -- (BUSINESS WIRE)--Oct. 24, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide third quarter financial results on , after the close of the market. A conference ... Cooley LLP served as legal advisor to Biote. DLA Piper LLP (US) served as legal advisor to Haymaker Acquisition Corp. III. About Biote . Biote is a woman-led company operating a high growth, differentiated medical practice-building business within the hormone optimization space. Biote trains practitioners how to identify and treat early indicators of …IRVING, Texas--(BUSINESS WIRE)--Jan. 5, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten public offering of its Class A common stock by certain of its stockholders at a price to the …biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that ...Nov 30, 2023 · Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business. The company offers end-to-end platform that provides practitioners with ...

Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ... Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business. The company offers end-to-end platform that provides practitioners with ...Biote’s corporate headquarters is at 1875 West Walnut Hill Lane, Suite 100 Irving, TX 75038. What is Biote’s fiscal year? Biote’s accounting follows a calendar year of January 1 to December 31. ... Biote’s transfer agent is Continental Stock Transfer & Trust Company.The Investor Relations website contains information about biote Corp's business for stockholders, potential investors, and financial analysts.biote Corp: Condensed Statements of Operations (in thousands) (unaudited) Three Months Ended, June 30, 2022. 2021. Total revenue $ 41,359 $ 34,750

Corporate Profile Biote operates a high growth, differentiated medical practice-building business within the hormone optimization space. Similar to a franchise model, Biote provides the necessary components to enable practitioners to establish, build, and successfully operate a hormone optimization center to treat patients appropriate for therapy.

Amended and Restated Investor Rights Agreement . On July 19, 2022, biote Corp. (the “Company”) entered into an Amended and Restated Investor Rights Agreement, by and among the Company, Haymaker Sponsor III LLC (the “Sponsor”) and the other partiers thereto (the “A&R IRA”), which amends and restates the Investor Rights Agreement dated as of May 26, 2022 (the “Prior IRA”), by and ...For the reasons described above, we caution you against relying on any forward-looking statements, which should also be read in conjunction with Part I, Item 1A, “Risk Factors”, in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “Annual Report”), and Part II, Item 1A in this Quarterly Report and the other cautionary …In December 2021, Biote entered into a business combination agreement with Haymaker Acquisition Corp. III (Nasdaq: HYAC), which is expected to close in the second quarter of 2022. 2022 guidance of $160-166 million in …Feb 9, 2023 · IRVING, Texas--(BUSINESS WIRE)--Feb. 9, 2023-- Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market. Biote Q4 Earnings Conference Call. March 29, 2023. Click here for webcast. Fourth Quarter and Full Year 2022 Earnings Call Transcript.Dec 1, 2023 · A high-level overview of biote Corp. (BTMD) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. As previously disclosed, on May 9, 2023, biote Corp. (the “ Company ”), commenced (i) its offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), of the Company, at an exercise price of $11.50 per share (the “ …Aug 24, 2022 · August 24, 2022 08:30 AM Eastern Daylight Time. IRVING, Texas-- ( BUSINESS WIRE )-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business ... Terry joined Biote to drive permanent industry innovation in the hormone optimization market, addressing the 200 million individuals in the U.S. who suffer from hormone imbalance. Terry’s team-first focus has consistently resulted in growth, both in the financials of the $100 million to $2.5 billion companies she has led, and in the personal ...Jun 27, 2023 ... Biote is a company that specializes in hormone optimization using bioidentical hormone pellets, explains David J. Watson, M.D., an OB-GYN at ...

Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 May. 09: CI Certain Restricted Stock Units of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023. Apr. 05: CI Certain Stock Options of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023.

Corporate Profile Biote operates a high growth, differentiated medical practice-building business within the hormone optimization space. Similar to a franchise …

Haymaker management is a uniquely qualified team boasting C-suite operational experience at Fortune 500 companies and deep knowledge in both public and private equity investing. Haymaker executives have experience in public and private equity as well as operations and strategy, making them an ideal manager and sponsor for a new public company.Saint Barbara is the patron saint of Marine artillerymen. She is also recognized by Marine Corps Aviation ordnancemen. Saint Michael is the patron saint of the armed forces.NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) — Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the “Business Combination”) with Biote, and the …CBS’s hit series NCIS is a police procedural that follows a fictional group of special agents tasked with solving crimes related to the United States Department of the Navy (which includes the Marine Corps).Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business. The company offers end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support.Biote is a hormone optimization company that has translated over 80 years of scientific insight into clinically-validated medical approaches that identify ...Management reiterates its 2022 guidance of $160-166 million in revenue and $46-50 million in adjusted EBITDA. 1. IRVING, TX, May 11, 2022 – Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced financial results for the first quarter of 2022.biote Corp stock performance at a glance. Check biote Corp’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. WHO IS BIOTE? Biote is a leading innovator in precision and preventive medicine. For patients, it is a way for them to take control of their health through hormone optimization. For providers, it’s a way to learn how to identify and address the earliest indicators of aging.*Track biote Corp (BTMD) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable ...Biote Corporate Fourth Quarter and Full Year 2022 Earnings Call ... Biote generated full year 2022 revenue and adjusted EBITDA of $165 million and $50.1 million respectively, representing growth of 18.3% and 24.6% respectively from 2021. The strong annual performance was capped off by solid fourth quarter results consistent with our ...America’s largest Marine Corps bases include North Carolina’s Marine Corps Base Camp Lejeune, and California’s Marine Corps Air Ground Combat Center Twentynine Palms and Marine Corps Base Camp Pendleton.

IRVING, Texas--(BUSINESS WIRE)--May 31, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced its participation at the following investor conferences: . On June 6, 2023, Terry Weber, Biote’s Chief …Jun 17, 2022 · IRVING, Texas--(BUSINESS WIRE)--Jun. 5, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten offering of 5,217,392 shares of its Class A common stock by one its stockholders at a ... As previously disclosed, on May 9, 2023, biote Corp. (the “ Company ”), commenced (i) its offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), of the Company, at an exercise price of $11.50 per share (the “ Warrants ”), the opportunity to receive 0.23 shares of Common ...Instagram:https://instagram. best tech stockvoo stock forecastdental insurance plans pennsylvanialist of companies on the sandp 500 IRVING, Texas, October 24, 2023--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leading provider of hormone optimization, today announced the Company …IRVING, Texas--(BUSINESS WIRE)--May 9, 2023-- Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating … lowest float stocksdave ramsay books BIGBEAR AI HOLDINGS CORP. BBAI. Technology. BIOATLA. BCAB. Health Care. BIOMEA FUSION. BMEA. Health Care. BIOTE CORP. BTMD. Health Care. BIOVIE. BIVI. Health ... how to read candlestick chart May 9, 2023 · Biote Corp. Consolidated Statements of Operations (In Thousands, except per share values) (Unaudited) Three Months Ended March 31, 2023. 2022. Revenue: Product revenue $ 44,155 $ 36,758. Service ... IRVING, Texas -- (BUSINESS WIRE)--Aug. 24, 2022-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. Mr.